# Cardiorenal Fibrosis: Biology and Therapeutics

> **NIH NIH R01** · MAYO CLINIC ROCHESTER · 2020 · $397,500

## Abstract

PROJECT SUMMARY
The objective of this application is to reduce the burden of cardiorenal fibrosis and dysfunction through the use
of an innovative therapeutic peptide strategy via the activation of the particulate guanylyl cyclase B (GC-B)
receptor. Another key component of this proposal is to clarify the important interaction between the heart and
kidney and the fibrotic mechanisms that manifests in both organs due to cardiovascular disease (CVD) or
chronic kidney disease (CKD). Increasing evidence has demonstrated that cardiorenal fibrosis is a hallmark of
CVD and CKD and there is an evolving paradigm that disease in one organ, either the heart or kidney, induces
fibrosis and functional impairment of the other organ. Yet, the pathophysiological mechanism that elicits this
fibrotic phenotype simultaneously in both organs is not understood and if left untreated, manifests clinically as
cardiorenal syndrome. Thus a real urgency exists to develop effective anti-fibrotic therapeutic strategies to
reduce the risk of both heart and kidney failure. Accordingly, studies have supported that the GC-B/cGMP
pathway, activated by endothelial and renal-derived C-type natriuretic peptide (CNP), functions as a key
regulator of fibrosis by inhibiting fibroblast proliferation and collagen synthesis, suppressing pro-fibrotic factors
and preserving endothelial/vascular integrity. Additionally, we have recently reported that urinary CNP is
elevated with fibrotic disease or injury, thus suggesting the potential for urinary CNP to serve as a novel, non-
invasive fibrosis biomarker. Here we advance our novel first-in-class GC-B activator, C53, as an innovative
therapeutic peptide strategy for cardiorenal fibrosis. Our preliminary studies demonstrate that C53 possesses
potent cGMP-generating actions via selective GC-B receptor activation and has a longer circulating half-live,
than biologically active CNP. Thus, C53 may represent an advanced drug design strategy that overcomes the
limitation of native CNP's low bioavailability. Our central hypothesis is that chronic administration of the novel
GC-B peptide activator, C53, can interrupt the cascade of cellular fibro-stimulatory responses in the heart and
kidney that culminate in cardiorenal fibrosis and dysfunction triggered by disease in the heart (CVD) or kidney
(CKD). This proposal will also define urinary CNP as a non-invasive biomarker for cardiorenal fibrotic
remodeling in human myocardial and renal disease. The impact of our translational application is high,
addressing the need for new drugs and biomarkers for cardiorenal fibrosis of which there are no effective
strategies to treat or detect this disease phenotype. Our Specific Aims are as follows: Aim 1: To establish the
cellular mechanisms by which C53 exerts its anti-fibrotic actions on human cardiac and renal fibroblasts in
vitro. Aim 2: To establish in vivo, that chronic subcutaneous infusion of C53 will prevent adverse cardiorenal
fibrosis and dysfunction i...

## Key facts

- **NIH application ID:** 9908154
- **Project number:** 5R01HL132854-05
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** Sasantha Jeson Sangaralingham
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $397,500
- **Award type:** 5
- **Project period:** 2016-07-01 → 2022-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9908154

## Citation

> US National Institutes of Health, RePORTER application 9908154, Cardiorenal Fibrosis: Biology and Therapeutics (5R01HL132854-05). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9908154. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*